Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer

Kaoru Kitamura, Hiroshi Saeki, Hidetoshi Kawaguchi, Koshi Araki, Shinji Ohno, Hiroyuki Kuwano, Yoshihiko Maehara, Keizo Sugimachi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background/aims: The prediction of an effective adjuvant therapy is essential in order to increase the number of esophageal cancer cases demonstrating an excellent response. Correlation of the immunohistochemical expression of p53 protein and Ki-67 antigen were studied using biopsied specimens of advanced esophageal cancer. The combined staining status of both can help predict the efficacy of neoadjuvant therapy in patients with esophageal cancer. Methodology: The overexpression of p53 protein and the Ki-67 labeling percentage were immunohistochemically investigated in 95 biopsied specimens of advanced esophageal carcinoma resected between 1998 and 1996. All patients preoperatively received 1 course of either chemoradiotherapy or hyperthermo-chemoradiotherapy. Results: Thirty-nine specimens were positive for p53 protein staining (41.1%), and the treatment modalities were histopathologically effective in 71.8% of these 39 patients (28/39), while the efficiency rate was 58.9% (33/56) in patients with p53(-). On the other hand, the efficiency rate of patients with a high Ki-67 labeling percentage (≥ 30%) was 73.9%, which was significantly higher than that of those with a low Ki-67 labeling percentage (< 30%) (38.5%, P = 0.0013). The efficacy rate of the patients with both a high Ki-67 labeling percentage and p53(+) was 80%, while that of the patients with a low Ki-67 labeling percentage and p53 (-) was only 35.3% (P = 0.0098). The combination of a high Ki-67 labeling percentage and p53(-) particularly showed a high sensitivity to hyperthermo-chemoradiotherapy since the efficiency rate of these patients with hyperthermo-chemoradiotherapy was 81.5%, while the rate for those with chemoradiotherapy was 41.7% (P = 0.0129). Conclusions: An immunohistochemical analysis of p53 and the Ki-67 labeling percentage using biopsied specimens was thus found to effectively predict the efficacy of neoadjuvant therapies in patients with esophageal cancer.

Original languageEnglish
Pages (from-to)419-423
Number of pages5
JournalHepato-gastroenterology
Volume47
Issue number32
Publication statusPublished - May 3 2000

Fingerprint

Ki-67 Antigen
Neoadjuvant Therapy
Esophageal Neoplasms
Chemoradiotherapy
Proteins
Staining and Labeling
Carcinoma

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. / Kitamura, Kaoru; Saeki, Hiroshi; Kawaguchi, Hidetoshi; Araki, Koshi; Ohno, Shinji; Kuwano, Hiroyuki; Maehara, Yoshihiko; Sugimachi, Keizo.

In: Hepato-gastroenterology, Vol. 47, No. 32, 03.05.2000, p. 419-423.

Research output: Contribution to journalArticle

Kitamura, K, Saeki, H, Kawaguchi, H, Araki, K, Ohno, S, Kuwano, H, Maehara, Y & Sugimachi, K 2000, 'Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer', Hepato-gastroenterology, vol. 47, no. 32, pp. 419-423.
Kitamura, Kaoru ; Saeki, Hiroshi ; Kawaguchi, Hidetoshi ; Araki, Koshi ; Ohno, Shinji ; Kuwano, Hiroyuki ; Maehara, Yoshihiko ; Sugimachi, Keizo. / Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. In: Hepato-gastroenterology. 2000 ; Vol. 47, No. 32. pp. 419-423.
@article{fb04da768f6a437bb6391727ca4e035d,
title = "Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer",
abstract = "Background/aims: The prediction of an effective adjuvant therapy is essential in order to increase the number of esophageal cancer cases demonstrating an excellent response. Correlation of the immunohistochemical expression of p53 protein and Ki-67 antigen were studied using biopsied specimens of advanced esophageal cancer. The combined staining status of both can help predict the efficacy of neoadjuvant therapy in patients with esophageal cancer. Methodology: The overexpression of p53 protein and the Ki-67 labeling percentage were immunohistochemically investigated in 95 biopsied specimens of advanced esophageal carcinoma resected between 1998 and 1996. All patients preoperatively received 1 course of either chemoradiotherapy or hyperthermo-chemoradiotherapy. Results: Thirty-nine specimens were positive for p53 protein staining (41.1{\%}), and the treatment modalities were histopathologically effective in 71.8{\%} of these 39 patients (28/39), while the efficiency rate was 58.9{\%} (33/56) in patients with p53(-). On the other hand, the efficiency rate of patients with a high Ki-67 labeling percentage (≥ 30{\%}) was 73.9{\%}, which was significantly higher than that of those with a low Ki-67 labeling percentage (< 30{\%}) (38.5{\%}, P = 0.0013). The efficacy rate of the patients with both a high Ki-67 labeling percentage and p53(+) was 80{\%}, while that of the patients with a low Ki-67 labeling percentage and p53 (-) was only 35.3{\%} (P = 0.0098). The combination of a high Ki-67 labeling percentage and p53(-) particularly showed a high sensitivity to hyperthermo-chemoradiotherapy since the efficiency rate of these patients with hyperthermo-chemoradiotherapy was 81.5{\%}, while the rate for those with chemoradiotherapy was 41.7{\%} (P = 0.0129). Conclusions: An immunohistochemical analysis of p53 and the Ki-67 labeling percentage using biopsied specimens was thus found to effectively predict the efficacy of neoadjuvant therapies in patients with esophageal cancer.",
author = "Kaoru Kitamura and Hiroshi Saeki and Hidetoshi Kawaguchi and Koshi Araki and Shinji Ohno and Hiroyuki Kuwano and Yoshihiko Maehara and Keizo Sugimachi",
year = "2000",
month = "5",
day = "3",
language = "English",
volume = "47",
pages = "419--423",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "32",

}

TY - JOUR

T1 - Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer

AU - Kitamura, Kaoru

AU - Saeki, Hiroshi

AU - Kawaguchi, Hidetoshi

AU - Araki, Koshi

AU - Ohno, Shinji

AU - Kuwano, Hiroyuki

AU - Maehara, Yoshihiko

AU - Sugimachi, Keizo

PY - 2000/5/3

Y1 - 2000/5/3

N2 - Background/aims: The prediction of an effective adjuvant therapy is essential in order to increase the number of esophageal cancer cases demonstrating an excellent response. Correlation of the immunohistochemical expression of p53 protein and Ki-67 antigen were studied using biopsied specimens of advanced esophageal cancer. The combined staining status of both can help predict the efficacy of neoadjuvant therapy in patients with esophageal cancer. Methodology: The overexpression of p53 protein and the Ki-67 labeling percentage were immunohistochemically investigated in 95 biopsied specimens of advanced esophageal carcinoma resected between 1998 and 1996. All patients preoperatively received 1 course of either chemoradiotherapy or hyperthermo-chemoradiotherapy. Results: Thirty-nine specimens were positive for p53 protein staining (41.1%), and the treatment modalities were histopathologically effective in 71.8% of these 39 patients (28/39), while the efficiency rate was 58.9% (33/56) in patients with p53(-). On the other hand, the efficiency rate of patients with a high Ki-67 labeling percentage (≥ 30%) was 73.9%, which was significantly higher than that of those with a low Ki-67 labeling percentage (< 30%) (38.5%, P = 0.0013). The efficacy rate of the patients with both a high Ki-67 labeling percentage and p53(+) was 80%, while that of the patients with a low Ki-67 labeling percentage and p53 (-) was only 35.3% (P = 0.0098). The combination of a high Ki-67 labeling percentage and p53(-) particularly showed a high sensitivity to hyperthermo-chemoradiotherapy since the efficiency rate of these patients with hyperthermo-chemoradiotherapy was 81.5%, while the rate for those with chemoradiotherapy was 41.7% (P = 0.0129). Conclusions: An immunohistochemical analysis of p53 and the Ki-67 labeling percentage using biopsied specimens was thus found to effectively predict the efficacy of neoadjuvant therapies in patients with esophageal cancer.

AB - Background/aims: The prediction of an effective adjuvant therapy is essential in order to increase the number of esophageal cancer cases demonstrating an excellent response. Correlation of the immunohistochemical expression of p53 protein and Ki-67 antigen were studied using biopsied specimens of advanced esophageal cancer. The combined staining status of both can help predict the efficacy of neoadjuvant therapy in patients with esophageal cancer. Methodology: The overexpression of p53 protein and the Ki-67 labeling percentage were immunohistochemically investigated in 95 biopsied specimens of advanced esophageal carcinoma resected between 1998 and 1996. All patients preoperatively received 1 course of either chemoradiotherapy or hyperthermo-chemoradiotherapy. Results: Thirty-nine specimens were positive for p53 protein staining (41.1%), and the treatment modalities were histopathologically effective in 71.8% of these 39 patients (28/39), while the efficiency rate was 58.9% (33/56) in patients with p53(-). On the other hand, the efficiency rate of patients with a high Ki-67 labeling percentage (≥ 30%) was 73.9%, which was significantly higher than that of those with a low Ki-67 labeling percentage (< 30%) (38.5%, P = 0.0013). The efficacy rate of the patients with both a high Ki-67 labeling percentage and p53(+) was 80%, while that of the patients with a low Ki-67 labeling percentage and p53 (-) was only 35.3% (P = 0.0098). The combination of a high Ki-67 labeling percentage and p53(-) particularly showed a high sensitivity to hyperthermo-chemoradiotherapy since the efficiency rate of these patients with hyperthermo-chemoradiotherapy was 81.5%, while the rate for those with chemoradiotherapy was 41.7% (P = 0.0129). Conclusions: An immunohistochemical analysis of p53 and the Ki-67 labeling percentage using biopsied specimens was thus found to effectively predict the efficacy of neoadjuvant therapies in patients with esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034003286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034003286&partnerID=8YFLogxK

M3 - Article

C2 - 10791203

AN - SCOPUS:0034003286

VL - 47

SP - 419

EP - 423

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 32

ER -